Checklist for assessing OBMEA feasibility in rare diseases
A checklist to help determine if an Oblique Meta-Analysis (OBMEA) is feasible when evaluating health technologies in rare diseases, where data is often limited.
At a glance
Use when
When traditional meta-analysis methods are not feasible due to limited or heterogeneous data in rare diseases
Avoid when
When sufficient direct comparative evidence is available for standard meta-analysis
Inputs
Information on available evidence, study designs, data quality, and patient population characteristics in rare diseases
Outputs
Assessment of whether OBMEA is a feasible approach for a given rare disease context
How it works
The document appears to be a PDF containing a checklist or guideline for assessing the feasibility of conducting an Oblique Meta-Analysis (OBMEA) in the context of rare diseases. It likely includes criteria related to data availability, study design compatibility, statistical considerations, and methodological challenges specific to rare disease settings.
- Project
- IMPACT HTA
- Funding
- Horizon 2020
- Project status
- Completed 2021
- HTA domains
- Aspects Beyond HTA
- Categories
- Pricing/Payer
- Technology
- Medicines
Questions this answers
- › What factors should be considered when deciding to use OBMEA in rare diseases?
- › How can we assess whether enough data exists for an OBMEA in a rare disease context?
- › What are the methodological challenges of applying OBMEA to rare diseases?
- › Can OBMEA be used when traditional meta-analysis is not possible due to sparse data?
- › What study designs are suitable for inclusion in an OBMEA for rare diseases?
- › How does the rarity of a disease affect the feasibility of performing an OBMEA?
Related methods
Similar by meaning
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.